Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1974 1
1975 2
1976 2
1977 3
1978 3
1979 1
1980 5
1983 4
1984 1
1985 2
1986 1
1987 2
1988 1
1989 2
1990 3
1991 3
1992 2
1993 2
1994 2
1995 1
1996 5
1997 2
1998 2
1999 1
2000 4
2002 3
2003 1
2004 2
2005 1
2006 5
2007 7
2008 1
2009 3
2010 2
2011 2
2012 1
2013 1
2014 1
2017 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Daver NG, et al. Among authors: ott mg. Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362. Blood. 2023. PMID: 36265087 Free PMC article. Clinical Trial.
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Konopleva MY, et al. Among authors: ott mg. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):364-374. doi: 10.1016/j.clml.2024.01.007. Epub 2024 Jan 18. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38378362 Free article. Clinical Trial.
Issues in diisocyanate antibody testing.
Ott MG, Jolly AT, Burkert AL, Brown WE. Ott MG, et al. Crit Rev Toxicol. 2007;37(7):567-85. doi: 10.1080/10408440701419553. Crit Rev Toxicol. 2007. PMID: 17674212 Review.
Progress and prospects: gene therapy clinical trials (part 1).
Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S. Alexander BL, et al. Among authors: ott mg. Gene Ther. 2007 Oct;14(20):1439-47. doi: 10.1038/sj.gt.3303001. Gene Ther. 2007. PMID: 17909539 Review.
Gene therapy for chronic granulomatous disease.
Stein S, Siler U, Ott MG, Seger R, Grez M. Stein S, et al. Among authors: ott mg. Curr Opin Mol Ther. 2006 Oct;8(5):415-22. Curr Opin Mol Ther. 2006. PMID: 17078383 Review.
88 results